Literature DB >> 20943957

Antifibrotic properties of c-Ski and its regulation of cardiac myofibroblast phenotype and contractility.

Ryan H Cunnington1, Baiqiu Wang, Saeid Ghavami, Krista L Bathe, Sunil G Rattan, Ian M C Dixon.   

Abstract

Cardiac myofibroblasts are key players in chronic remodeling of the cardiac extracellular matrix, which is mediated in part by elevated transforming growth factor-β₁ (TGF-β₁). The c-Ski proto-oncoprotein has been shown to modify TGF-β₁ post-receptor signaling through receptor-activated Smads (R-Smads); however, little is known about how c-Ski regulates fibroblast phenotype and function. We sought to elucidate the function of c-Ski in primary cardiac myofibroblasts using a c-Ski overexpression system. Cardiac myofibroblasts expressed three forms of c-Ski with the predominant band at 105 kDa, and adenoviral c-Ski treatment resulted in overexpression of 95-kDa c-Ski in cellular nuclei. Exogenous c-Ski led to significant inhibition of type I collagen secretion and myofibroblast contractility using two-dimensional semifloating gel contraction assay in both basal and with TGF-β₁ (10 ng/ml for 24 h) stimulation. Overexpressed c-Ski did not inhibit nuclear translocation of phosphorylated R-Smad2, despite their binding, as demonstrated by immunoprecipitation. Acute treatment of primary myofibroblasts with TGF-β₁ in vitro revealed a marked nuclear shuttling of c-Ski at 24 and 48 h following stimulation. Remarkably, overexpression of c-Ski led to a stepwise reduction of the myofibroblast marker α-smooth muscle actin with increasing multiplicity of infection, and these results indicate that 95-kDa c-Ski overexpression may effect a loss of the myofibroblastic phenotype. Furthermore, adenovirus (Ad) for hemagglutinin-tagged c-Ski infection led to a reduction in the number of myofibroblasts versus Ad-LacZ-infected and uninfected controls, due to induction of apoptosis. Finally, we observed a significant increase in 105-kDa c-Ski in the cytosolic fraction of cells of the infarct scar and adjacent remnant myocardium vs. noninfarcted controls.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20943957     DOI: 10.1152/ajpcell.00050.2010

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  25 in total

Review 1.  Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver.

Authors:  Hassan K Awada; Mintai P Hwang; Yadong Wang
Journal:  Biomaterials       Date:  2015-12-29       Impact factor: 12.479

2.  The miR-214-3p/c-Ski axis modulates endothelial-mesenchymal transition in human coronary artery endothelial cells in vitro and in mice model in vivo.

Authors:  Juan Wang; Hongjian Li; Zhongying Lv; Xiaomei Luo; Wei Deng; Ting Zou; Yue Zhang; Wanyue Sang; Xuehua Wang
Journal:  Hum Cell       Date:  2022-01-03       Impact factor: 4.174

3.  Profibrotic activities for matrix metalloproteinase-8 during bleomycin-mediated lung injury.

Authors:  Vanessa J Craig; Pablo A Quintero; Susanne E Fyfe; Avignat S Patel; Martin D Knolle; Lester Kobzik; Caroline A Owen
Journal:  J Immunol       Date:  2013-03-13       Impact factor: 5.422

4.  Human mesenchymal stem cells express a myofibroblastic phenotype in vitro: comparison to human cardiac myofibroblasts.

Authors:  Melanie A Ngo; Alison Müller; Yun Li; Shannon Neumann; Ganghong Tian; Ian M C Dixon; Rakesh C Arora; Darren H Freed
Journal:  Mol Cell Biochem       Date:  2014-04-02       Impact factor: 3.396

5.  SnoN residue (1-366) attenuates hypertrophic scars through resistance to transforming growth factor-β1-induced degradation.

Authors:  Gui-Fang Sun; Hong-Chang Li; Yue-Ping Zhan; Xiao-Fen Zhang; Li-Yun Pan; Ya-Feng Chen; Ke Xu; Dian-Xu Feng
Journal:  Lab Invest       Date:  2019-08-13       Impact factor: 5.662

Review 6.  Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease.

Authors:  Robert G Gourdie; Stefanie Dimmeler; Peter Kohl
Journal:  Nat Rev Drug Discov       Date:  2016-06-24       Impact factor: 84.694

Review 7.  Therapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic disease.

Authors:  Natalie Sampson; Peter Berger; Christoph Zenzmaier
Journal:  Oxid Med Cell Longev       Date:  2012-10-22       Impact factor: 6.543

8.  Function and fate of myofibroblasts after myocardial infarction.

Authors:  Neil A Turner; Karen E Porter
Journal:  Fibrogenesis Tissue Repair       Date:  2013-03-01

9.  CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis.

Authors:  Mehrnaz Gharaee-Kermani; Sathish Kasina; Bethany B Moore; Dafydd Thomas; Rohit Mehra; Jill A Macoska
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

10.  Common threads in cardiac fibrosis, infarct scar formation, and wound healing.

Authors:  Michael P Czubryt
Journal:  Fibrogenesis Tissue Repair       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.